As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
11 Analysts have issued a Innoviva forecast:
11 Analysts have issued a Innoviva forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 370 370 |
12%
12%
|
|
| Gross Profit | 321 321 |
11%
11%
|
|
| EBITDA | 217 217 |
34%
34%
|
|
| EBIT (Operating Income) EBIT | 177 177 |
30%
30%
|
|
| Net Profit | 39 39 |
73%
73%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
| Head office | United States |
| CEO | Mr. Raifeld |
| Employees | 127 |
| Founded | 1996 |
| Website | www.inva.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


